MedTrace Logo

Study of STP938 in Advanced Solid Tumours

NCT06297525 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-04-23

No results posted yet for this study

Summary

The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy.

The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.

Conditions

Interventions

DRUG

STP938

Small molecule

Sponsors & Collaborators

  • Step Pharma, SAS

    lead INDUSTRY

Principal Investigators

  • Maureen Higgins · Step Pharma

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-02
Primary Completion
2026-12-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States
  • France
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06297525 on ClinicalTrials.gov